Market Place
Sourcing Support
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
15 Jan 2025 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Jan 2025 //
BUSINESSWIRE
Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer
30 Dec 2024 //
BUSINESSWIRE
Verastem Provides Update on RAMP 203 Trial in KRAS G12C Lung Cancer
18 Dec 2024 //
BUSINESSWIRE
Verastem to Present at Evercore ISI HealthCONx Conference
26 Nov 2024 //
BUSINESSWIRE
Verastem Oncology Reports Q3 2024 Results & Business Updates
06 Nov 2024 //
BUSINESSWIRE
Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
31 Oct 2024 //
BUSINESSWIRE
Verastem Presents Updated Data For Avutometinib In Ovarian Cancer
17 Oct 2024 //
BUSINESSWIRE
Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024
09 Oct 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Oct 2024 //
BUSINESSWIRE
Verastem To Present RAMP 201 Data At IGCS 2024 Meeting
10 Sep 2024 //
BUSINESSWIRE
Verastem and STAAR Launch Low-Grade Serous Ovarian Cancer Awareness Day
03 Sep 2024 //
BUSINESSWIRE
Verastem sets first awareness day for rare form of ovarian cancer
03 Sep 2024 //
FIERCE PHARMA
Verastem Oncology Reports Q2 2024 Results And Business Updates
08 Aug 2024 //
BUSINESSWIRE
Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
29 Jul 2024 //
BUSINESSWIRE
Verastem Announces Proposed Public Offering Of Stock And Warrants
23 Jul 2024 //
BUSINESSWIRE
Verastem Prices $55M Public Offering Of Stock And Warrants
23 Jul 2024 //
BUSINESSWIRE
Verastem Doses First Patient With GFH375/VS-7375 In China Phase 1/2 Trial
12 Jul 2024 //
BUSINESSWIRE
Verastem Oncology Grants Inducement Awards Under Nasdaq Rule 5635(c)(4)
08 Jul 2024 //
BUSINESSWIRE
Verastem Oncology Added To Russell 3000 And Microcap Indexes
01 Jul 2024 //
BUSINESSWIRE
Verastem`s begins rolling sub of NDA to USFDA of avutometinib & defactinib combo
28 May 2024 //
PHARMABIZ
ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success
25 May 2024 //
CLINICALTRIALSARENA
Verastem Nda Initiation: Avutometinib Defactinib Combo Rolling Submission
24 May 2024 //
BUSINESSWIRE
Verastem Pancreatic Interim Positive: Avutometinib Defactinib Chemo Combo
23 May 2024 //
BUSINESSWIRE
Verastem Oncology Q1 2024 Financials, Business Update
09 May 2024 //
BUSINESSWIRE
Verastem Oncology At RBC Healthcare Conference
07 May 2024 //
BUSINESSWIRE
Verastem Oncology Appoints John Hayslip As Chief Medical Officer
18 Apr 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
BUSINESSWIRE
Results Reveal Negative Impact on Well-Being for People Living with LGSOC
18 Mar 2024 //
BUSINESSWIRE
Verastem survey shows toll rare cancer takes on well-being
18 Mar 2024 //
FIERCE PHARMA
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
BUSINESSWIRE
Verastem Announces Multiple Oral Presentations at SGO 2024 Annual Meeting
11 Mar 2024 //
BUSINESSWIRE
Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone
05 Mar 2024 //
BUSINESSWIRE
Verastem Oncology Outlines Key 2024 Strategic Priorities
29 Jan 2024 //
BUSINESSWIRE
Verastem Granted Fast Track Designation for Avutometinib and Sotorasib
18 Jan 2024 //
BUSINESSWIRE
Verastem Oncology to Participate in B. Riley Securities 4th Oncology Conference
11 Jan 2024 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
BUSINESSWIRE
Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib
13 Dec 2023 //
BUSINESSWIRE
Verastem Oncology Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib
06 Nov 2023 //
BUSINESSWIRE
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
26 Oct 2023 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Oct 2023 //
BUSINESSWIRE
Verastem Announces Results of RAMP 203 Trial of Avutometinib and LUMAKRAS
14 Oct 2023 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Oct 2023 //
BUSINESSWIRE
Verastem Presents Avutometinib and Defactinib Combination Program Updates
28 Sep 2023 //
BUSINESSWIRE
Verastem Oncology to Participate in Upcoming Investor Conferences
05 Sep 2023 //
BUSINESSWIRE
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet
28 Aug 2023 //
BUSINESSWIRE
Verastem Oncology Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
11 Jul 2023 //
BUSINESSWIRE
Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2023 //
BUSINESSWIRE
Verastem Oncology Announces Design for Trial of Avutometinib and Defactinib
05 Jul 2023 //
BUSINESSWIRE
Verastem Oncology Announces Pricing of $85.0 Million Public Offering
16 Jun 2023 //
BUSINESSWIRE
Verastem Oncology Announces Proposed PO of Common Stock and Pre-Funded Warrants
15 Jun 2023 //
BUSINESSWIRE
Verastem Oncology Announces Reverse Stock Split
31 May 2023 //
BUSINESSWIRE
Updated Data from Verastem`s RAMP 201 Trial Show Objective Response Rate of 45%
25 May 2023 //
BUSINESSWIRE
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
16 May 2023 //
BUSINESSWIRE
Verastem Oncology Reports1Q 2023 FYR and Highlights Recent Company Progress
09 May 2023 //
BUSINESSWIRE
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial
26 Apr 2023 //
BUSINESSWIRE
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
18 Apr 2023 //
BUSINESSWIRE
